Probiotics and Nutraceuticals in Human Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2379

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
Interests: autophagy and protein metabolism in cancer and in neurodegeneration; epigenetics in cancer; nutraceuticals and probiotics in cancer and infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Human districts exposed to the exterior such as the skin, the digestive tract (from mouth to the intestine), and the vagina are colonized by bacteria, viruses, and fungi that as a whole are referred to as the microbiota. With their metabolism, these microbes produce beneficial nutrients and signaling molecules, yet in circumstances causing dysbiosis, they can promote diseases. Dysbiosis, the alteration in the equilibrium within the microbiota community and the microbiota metabolism, arises from changes in the environment brought forth by infections or unhealthy dietary habits, or abuse of antibiotics. Probiotics and nutraceuticals may help to restore the correct microenvironment and thus help to prevent and to cure diseases.

In this Special Issue, we wish to collect original research and review articles highlighting the role and function of probiotics and nutraceuticals (natural products with therapeutic potential) in preventing and curing human chronic diseases such as autoimmune and inflammatory diseases, cancer, infections, and others. Particular emphasis will be on the biochemical/epigenetic/cellular mechanisms of action of probiotics and nutraceuticals and their interaction for explaining the beneficial effects.

Prof. Dr. Ciro Isidoro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiota
  • prebiotics
  • probiotics
  • nutraceuticals
  • natural products
  • autoimmune diseases
  • cancer
  • neurodegeneration
  • inflammation
  • infectious diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4687 KiB  
Article
The Role of Probiotic Bacillus Spores and Amino Acids with Immunoglobulins on a Rat Enteropathy Model
by Maria-Adriana Neag, Carmen-Stanca Melincovici, Adrian Catinean, Dana-Maria Muntean, Raluca-Maria Pop, Ioana-Corina Bocsan, Andrei-Otto Mitre, Mihai-Bogdan Cardos, Andreea-Ioana Inceu and Anca-Dana Buzoianu
Biomedicines 2022, 10(10), 2508; https://doi.org/10.3390/biomedicines10102508 - 7 Oct 2022
Viewed by 1793
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most widely used drugs due to their anti-inflammatory, analgesic and antipyretic pharmacological effects. Gastrointestinal side effects are some of the most severe and frequent side effects of NSAIDs. These depend on the balance of the [...] Read more.
Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most widely used drugs due to their anti-inflammatory, analgesic and antipyretic pharmacological effects. Gastrointestinal side effects are some of the most severe and frequent side effects of NSAIDs. These depend on the balance of the gut microbiome, the abundance of Gram-negative bacteria, and the amount of lipopolysaccharide released. Therefore, restoring or improving gut bacteria balance with probiotic supplements could prove to be an adjuvant therapy against mild NSAID-induced enteropathy. Twenty-five Wistar albino male rats were divided into five groups. The negative control group was administered carboxymethylcellulose and the positive control group diclofenac (DIC), 8 mg/kg for 7 days, which represented the enteropathy model. Treatment groups consisted of a combination of pro-biotic spores (MSB), amino acids and immunoglobulins supplement (MM), which were also administered for 7 days. We analyzed hepatic injury markers (AST, ALT) and creatinine, and inflammatory markers, IL-6, TNF-α, PGE2, iNOS, as well as total antioxidant capacity. The results obtained in the present study suggest that the modulation of the intestinal microbiota by administration of probiotics (Bacillus spores), alone or in combination with immunoglobulins and amino acids, represents an attractive therapy for the prevention of NSAID-induced enteropathy. Full article
(This article belongs to the Special Issue Probiotics and Nutraceuticals in Human Diseases)
Show Figures

Figure 1

Back to TopTop